Cancer Research and Treatment

Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma

Yunze Xu, Wen Kong, Ming Cao, Jieying Wang, Zaoyu Wang, Liang Zheng, Xiaoyu Wu, Rongrong Cheng, Wei He, Bo Yang, Baijun Dong, Jiahua Pan, Yonghui Chen, Jiwei Huang, Chen Jiang, Wei Zhai, Fangzhou Li, Ruohua Chen, Xiang Zhou, Guangyu Wu, Xiaochuan Geng, Ji

Navigating the Current Landscape of Non-Clear Cell Renal Cell Carcinoma: A Review of the Literature

CLC-Pred 2.0: A Freely Available Web Application for In Silico Prediction of Human Cell Line Cytotoxicity and Molecular Mechanisms of Action for Druglike Compounds

Alexey A. Lagunin, Anastasia V. Rudik, Pavel V. Pogodin, Polina I. Savosina, Olga A. Tarasova, Alexander V. Dmitriev, Sergey M. Ivanov, Nadezhda Y. Biziukova, Dmitry S. Druzhilovskiy, Dmitry A. Filimonov, Vladimir V. Poroikov

International Journal of Molecular Sciences.2023; 24(2): 1689. CrossRef

Fumarate hydratase-deficient renal cell carcinoma: A case report and literature review

Yi-Hsuan Huang, Nan-Haw Chow, Yu-Ting Yu, Wen-Pin Su

Journal of Cancer Research and Practice.2023; 10(1): 28. CrossRef

Urologic Clinics of North America.2023; 50(2): 205. CrossRef

Tumors masquerading as type 2 papillary renal cell carcinoma: pathologists’ ever-expanding differential diagnosis for a heterogeneous group of entities

Urologic Oncology: Seminars and Original Investigations.2022; 40(12): 499. CrossRef

Low-Grade Fumarate Hydratase-Deficient Renal Cell Carcinoma in a 30-Year-Old Female

Nicolas Wyvekens, William J. Anderson, Young X. Kim, Mark Carter, Michelle S. Hirsch

International Journal of Surgical Pathology.2022; 30(2): 184. CrossRef

Response to the Letter to the Editor Entitled “Do We Have Sufficient Evidence to Define Prognosis for ‘Low-grade’ Fumarate Hydratase-deficient Renal Cell Carcinoma?”

Steven C. Smith, Ameer Hamza, Deepika Sirohi, Mahul B. Amin

Advances in Anatomic Pathology.2022; 29(3): 181. CrossRef

A Phase II, Single-arm Trial of Sunitinib and Erlotinib in Advanced Renal Cell Carcinoma

Zizhen Feng, Brendan D. Curti, David I. Quinn, John M. Strother, Zunqiu Chen, Rebecca Agnor, Tomasz M. Beer, Christopher W. Ryan

Clinical Genitourinary Cancer.2022; 20(5): 415. CrossRef

Targeting strategies in the treatment of fumarate hydratase deficient renal cell carcinoma

Andrea Katharina Lindner, Gennadi Tulchiner, Andreas Seeber, Peter J. Siska, Martin Thurnher, Renate Pichler

MR Spectroscopy for Detecting Fumarate Hydratase Deficiency in Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome

Guangyu Wu, Guiqin Liu, Jianfeng Wang, Shihang Pan, Yuansheng Luo, Yunze Xu, Wen Kong, Peng Sun, Jianrong Xu, Wei Xue, Jin Zhang

Complete response of hereditary leiomyomatosis and renal cell cancer (HLRCC)-associated renal cell carcinoma to nivolumab and ipilimumab combination immunotherapy by: a case report

Yasuhiro Iribe, Mitsuko Furuya, Yousuke Shibata, Masato Yasui, Makoto Funahashi, Junichi Ota, Hiromichi Iwashita, Yoji Nagashima, Hisashi Hasumi, Narihiko Hayashi, Kazuhide Makiyama, Keiichi Kondo, Reiko Tanaka, Masahiro Yao, Noboru Nakaigawa

Genotypic and Phenotypic Characteristics of Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome in Korean Patients

Ja Young Seo, Jeong-Yeal Ahn, Bhumsuk Keam, Miso Kim, Shinkyo Yoon, Jae Lyun Lee, Kwonoh Park, Inkeun Park

Annals of Laboratory Medicine.2021; 41(2): 207. CrossRef

Integrated Molecular Characterization of Fumarate Hydratase–deficient Renal Cell Carcinoma

Guangxi Sun, Xingming Zhang, Jiayu Liang, Xiuyi Pan, Sha Zhu, Zhenhua Liu, Cameron M. Armstrong, Jianhui Chen, Wei Lin, Banghua Liao, Tianhai Lin, Rui Huang, Mengni Zhang, Linmao Zheng, Xiaoxue Yin, Ling Nie, Pengfei Shen, Jinge Zhao, Haoran Zhang, Jindon

Clinical Cancer Research.2021; 27(6): 1734. CrossRef

Durable Major Response With Pazopanib in Recurrent, Heavily Pretreated Metastatic Esthesioneuroblastoma Harboring a Fumarate Hydratase Mutation

Marianne Spengler, Megan Wheelden, Heath B. Mackley, Joseph J. Drabick

Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma

Andrew J. Wiele, Devaki Shilpa Surasi, Priya Rao, Kanishka Sircar, Xiaoping Su, Tharakeswara K. Bathala, Amishi Y. Shah, Eric Jonasch, Vince D. Cataldo, Giannicola Genovese, Jose A. Karam, Christopher G. Wood, Nizar M. Tannir, Pavlos Msaouel

Response to systemic therapy in fumarate hydratase–deficient renal cell carcinoma

Lucia Carril-Ajuria, Emeline Colomba, Luigi Cerbone, Carmen Romero-Ferreiro, Laurence Crouzet, Brigitte Laguerre, Constance Thibault, Cécile Vicier, Guillermo de Velasco, Aude Fléchon, Carolina Saldana, Patrick R. Benusiglio, Brigitte Bressac-de Pailleret

European Journal of Cancer.2021; 151: 106. CrossRef

Hereditary Leiomyomatosis and Renal Cell Cancer: Recent Insights Into Mechanisms and Systemic Treatment

Congwang Zhang, Lijun Li, Yipeng Zhang, Changchun Zeng

Hereditary leiomyomatosis and renal cell cancer presenting as urothelial carcinoma

Samuel B Reynolds, Rishi Charate, Quang L Nguyen, Padmini Moffett

Journal of Onco-Nephrology.2021; 5(3): 178. CrossRef

Das FH-defiziente Nierenzellkarzinom erweitert das Spektrum der papillären Tumoren in der Niere

To treat or not to treat: a clinical series of retinal arterial macroaneurysms

Wan-Hua Cho, Wei-Yu Chiang, Chih-Hsin Chen, Hsi-Kung Kuo

On the Shoulders of Giants: The Evolution of Renal Cell Carcinoma Treatment—Cytokines, Targeted Therapy, and Immunotherapy

Janice P. Dutcher, Ronan Flippot, Jaleh Fallah, Bernard Escudier

American Society of Clinical Oncology Educational Book.2020; (40): 418. CrossRef

Novel morphological and genetic features of fumarate hydratase deficient renal cell carcinoma in HLRCC syndrome patients with a tailored therapeutic approach

Nicolas Wyvekens, Nadejda Valtcheva, Axel Mischo, Birgit Helmchen, Thomas Hermanns, Matthias Choschzick, Andreas M. Hötker, Anita Rauch, Beda Mühleisen, Dilara Akhoundova, Achim Weber, Holger Moch, Niels J. Rupp

Genes, Chromosomes and Cancer.2020; 59(11): 611. CrossRef

Fumarate hydratase as a therapeutic target in renal cancer

Priyanka Kancherla, Michael Daneshvar, Rebecca A. Sager, Mehdi Mollapour, Gennady Bratslavsky

Expert Opinion on Therapeutic Targets.2020; 24(9): 923. CrossRef

Construct a circRNA/miRNA/mRNA regulatory network to explore potential pathogenesis and therapy options of clear cell renal cell carcinoma

Shuheng Bai, YinYing Wu, Yanli Yan, Shuai Shao, Jiangzhou Zhang, Jiaxin Liu, Beina Hui, Rui Liu, Hailin Ma, Xiaozhi Zhang, Juan Ren